EP4356903A1 — Microtablets comprising lansoprazole
Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2024-04-24 · 2y expired
What this patent protects
The present invention relates to pharmaceutical composition in the form of capsule having enteric coating microtablets comprising lansoprazole wherein microtablets further comprising at least one surfactant, at least one pH modifier and further at least other pharmaceutically exc…
USPTO Abstract
The present invention relates to pharmaceutical composition in the form of capsule having enteric coating microtablets comprising lansoprazole wherein microtablets further comprising at least one surfactant, at least one pH modifier and further at least other pharmaceutically excipient and wherein enteric coating comprising metacrylic acid copolymer dispersion. The capsule is obtained by a process which is free of solvent, the process is simple, rapid, cost effective, time-saving and industrially convenient process.
Drugs covered by this patent
- Dexilant (DEXLANSOPRAZOLE) · Takeda
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.